Shares of Wave Life Sciences Ltd. (NASDAQ:WVE – Get Free Report) have been given a consensus rating of “Buy” by the ten research firms that are covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a hold recommendation, eight have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $22.22.
A number of brokerages recently issued reports on WVE. HC Wainwright reiterated a “buy” rating and set a $22.00 price objective on shares of Wave Life Sciences in a research note on Wednesday, November 13th. JPMorgan Chase & Co. upped their price target on shares of Wave Life Sciences from $13.00 to $17.00 and gave the stock an “overweight” rating in a research report on Thursday, October 17th. Truist Financial raised their price objective on shares of Wave Life Sciences from $17.00 to $36.00 and gave the company a “buy” rating in a research report on Tuesday, November 12th. StockNews.com downgraded shares of Wave Life Sciences from a “hold” rating to a “sell” rating in a report on Wednesday, November 13th. Finally, Mizuho raised their price target on Wave Life Sciences from $19.00 to $22.00 and gave the company an “outperform” rating in a report on Thursday, November 21st.
View Our Latest Stock Analysis on WVE
Insider Buying and Selling at Wave Life Sciences
Institutional Investors Weigh In On Wave Life Sciences
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Wave Life Sciences by 23.4% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,512 shares of the company’s stock worth $37,000 after acquiring an additional 856 shares during the last quarter. Ameritas Investment Partners Inc. raised its position in Wave Life Sciences by 50.2% in the 1st quarter. Ameritas Investment Partners Inc. now owns 7,334 shares of the company’s stock worth $45,000 after purchasing an additional 2,451 shares during the period. Profund Advisors LLC bought a new stake in Wave Life Sciences in the second quarter worth about $53,000. Point72 DIFC Ltd purchased a new position in shares of Wave Life Sciences during the third quarter valued at approximately $98,000. Finally, Principal Financial Group Inc. bought a new position in shares of Wave Life Sciences during the second quarter valued at approximately $74,000. 89.73% of the stock is currently owned by hedge funds and other institutional investors.
Wave Life Sciences Price Performance
NASDAQ:WVE opened at $15.10 on Friday. The stock has a 50-day simple moving average of $12.49 and a two-hundred day simple moving average of $8.13. Wave Life Sciences has a 52-week low of $3.50 and a 52-week high of $16.74.
About Wave Life Sciences
Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.
Featured Articles
- Five stocks we like better than Wave Life Sciences
- Insider Selling Explained: Can it Inform Your Investing Choices?
- The Latest 13F Filings Are In: See Where Big Money Is Flowing
- How to Use the MarketBeat Stock Screener
- 3 Penny Stocks Ready to Break Out in 2025
- Most active stocks: Dollar volume vs share volume
- FMC, Mosaic, Nutrien: Top Agricultural Stocks With Big Potential
Receive News & Ratings for Wave Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Wave Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.